A
15.60
-0.71 (-4.32%)
| Previous Close | 16.31 |
| Open | 16.18 |
| Volume | 1,201,046 |
| Avg. Volume (3M) | 1,033,304 |
| Market Cap | 1,732,939,392 |
| Price / Sales | 0.660 |
| Price / Book | 6.30 |
| 52 Weeks Range | |
| Earnings Date | 7 May 2026 |
| Operating Margin (TTM) | 16,317.06% |
| Diluted EPS (TTM) | -3.10 |
| Quarterly Revenue Growth (YOY) | -99.60% |
| Total Debt/Equity (MRQ) | 0.69% |
| Current Ratio (MRQ) | 12.05 |
| Operating Cash Flow (TTM) | -206.98 M |
| Levered Free Cash Flow (TTM) | -182.62 M |
| Return on Assets (TTM) | -40.72% |
| Return on Equity (TTM) | -83.24% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Bullish |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Bullish | |
| Stock | Amylyx Pharmaceuticals, Inc. | Bullish | Bullish |
AIStockmoo Score
-0.6
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | -3.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -0.5 |
| Average | -0.63 |
|
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Growth |
| % Held by Insiders | 9.54% |
| % Held by Institutions | 85.89% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 34.00 (HC Wainwright & Co., 117.95%) | Buy |
| Median | 21.00 (34.62%) | |
| Low | 19.00 (B of A Securities, 21.80%) | Buy |
| Average | 24.67 (58.14%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 14.39 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 04 Mar 2026 | 34.00 (117.95%) | Buy | 15.05 |
| 10 Feb 2026 | 28.00 (79.49%) | Buy | 14.89 | |
| Stifel | 03 Mar 2026 | 21.00 (34.62%) | Buy | 14.11 |
| B of A Securities | 20 Feb 2026 | 19.00 (21.79%) | Buy | 14.01 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |